Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ALNYLAM PHARMACEUTICALS, INC. reported revenue of $3.71B, up 65.2% year over year. Operating margin was 13.5% and net margin 8.4%, on a free-cash-flow margin of 12.5% with capital expenditure at 1.6% of revenue. Every figure is computed directly from ALNY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3.71B | 13.5% | 8.4% |
| FY2024 | $2.25B | -7.9% | -12.4% |
| FY2023 | $1.83B | -15.4% | -24.1% |
| FY2022 | $1.04B | -75.7% | -109.0% |
| FY2021 | $844M | -83.9% | -101.0% |
How does ALNY compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: ABBV · ABCL · ABT · ABUS · ACAD · ACNT
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.